Brief: NKGen Biotech Announces Administration Of First Dose Of Troculeucel To Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program
21/02/2025 14:11
Feb 21 (Reuters) - Nkgen Biotech Inc NKGN.O :
* NKGEN BIOTECH ANNOUNCES ADMINISTRATION OF FIRST DOSE OF
TROCULEUCEL TO FRONTOTEMPORAL DEMENTIA PATIENT UNDER FDA-CLEARED
COMPASSIONATE USE PROGRAM
Source text: ID:nGNX96jCmY
Further company coverage: NKGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nkgen Biotech
See all newsBrief: Nkgen Biotech Expands Clinical Trial Site Network For Alzheimer’S Disease Program Across US
Brief: NKgen Biotech And Hekabio Enter Into Strategic Partnership
Brief: Nkgen Biotech Announces International And U.S. Expansion Of Phase 1/2A Troculeucel Alzheimer’S Trial
Brief: Nkgen Biotech Announces Administration Of First Dose Of Troculeucel To Stroke Patient Under FDA-Cleared Compassionate Use Program
Brief: NKGen Biotech Announces Administration Of First Dose Of Troculeucel To Frontotemporal Dementia Patient Under FDA-Cleared Compassionate Use Program